VectivBio shares are trading higher after Ironwood Pharmaceuticals announced it would acquire the company for $17 per share.
Portfolio Pulse from Benzinga Newsdesk
Ironwood Pharmaceuticals announced it would acquire VectivBio for $17 per share, causing VectivBio shares to trade higher.
May 22, 2023 | 11:49 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ironwood Pharmaceuticals announced the acquisition of VectivBio for $17 per share.
Ironwood Pharmaceuticals' acquisition of VectivBio may have a neutral short-term impact on its stock price, as the market digests the news and evaluates the potential benefits and risks of the acquisition.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
VectivBio shares are trading higher after Ironwood Pharmaceuticals announced it would acquire the company for $17 per share.
VectivBio's stock price is likely to increase in the short term due to the acquisition announcement by Ironwood Pharmaceuticals at a price of $17 per share, which is perceived as a positive development for the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100